SCHEMBL4773313

SCHEMBL4773313

O=[C]CCc1ccc(Cl)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.50
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
MAPK1 P28482 1/20 0.48
CYP2C19 P33261 1/20 0.48
CNR1 P21554 1/20 0.44
GGPS1 O95749 1/20 0.43
GPR84 Q9NQS5 1/20 0.43
DAO P14920 1/20 0.43
PDPK1 O15530 1/20 0.42
HPGD P15428 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
PYCR1 P32322 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL97595 0.87 ACLY (0.47) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL9818272 0.85 ACLY (0.49) IDO1
SCHEMBL11621292 0.80 IDO1 (0.65) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL28630653 0.80 IDO1 (0.50) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL4261946 0.79 CYP1A2 (0.57) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL1805717 0.77 IDO1 (0.56) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL1847891 0.76 IDO1 (0.46) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL5537535 0.75 TAAR1 (0.54) IDO1DAO
SCHEMBL29587149 0.74 IDO1 (0.58) IDO1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL7020135 0.74 IDO1 (0.58) IDO1CYP1A2CYP3A4CYP2C9MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed
EP-0796618-B1 Treatment and prophylaxis of pancreatitis SANKYO CO (JP) 2002-01-30 EP disclosed
WO-2000041690-A9 USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM UNIV CALIFORNIA (US) 2001-10-11 WO disclosed
WO-2000041690-A1 USE OF THIAZOLIDINEDIONES TO AMELIORATE THE ADVERSE CONSEQUENCES OF MYOCARDIAL ISCHEMIA ON MYOCARDIAL FUNCTION AND METABOLISM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-07-20 WO disclosed
US-5968960-A ANTIISCHEMIC AGENTS AND HYPOTENSIVE AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-10-19 US disclosed
US-5804590-A ADMINISTERING DERIVATIVES OF THIAZOLIDINE; ANTI-DIABETIC AGENTS. SANKYO COMPANY, LIMITED (JP) 1998-09-08 US disclosed
US-5753681-A INSULIN SENSITIZERS SANKYO COMPANY, LIMITED (JP) 1998-05-19 US disclosed
EP-0796618-A1 Treatment and prophylaxis of pancreatitis SANKYO COMPANY LIMITED (JP) 1997-09-24 EP disclosed
EP-0783888-A1 Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis SANKYO COMPANY LIMITED (JP) 1997-07-16 EP disclosed